Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still’s disease with a previous successful tocilizumab treatment-Reference-Cited by-同舟云学术

Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still’s disease with a previous successful tocilizumab treatment

Published:2021-02-22 Issue:2 Volume:5 Page:360-364
ISSN:2472-5625
Container-title:Modern Rheumatology Case Reports
language:en
Short-container-title:Modern Rheumatology Case Reports

Author:

Naniwa Taio¹²^ORCID,Uehara Koji¹²,Yamabe Toru¹²,Ohmura Shin-ichiro³

Affiliation:

1. Division of Rheumatology, Department of Internal Medicine, Nagoya City University Hospital, Nagoya, Japan

2. Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

3. Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/24725625.2020.1818961

Reference17 articles.

1. Reactive Hemophagocytic Syndrome in Adult-Onset Still Disease

2. Adult-Onset Still Disease

3. Macrophage activation syndrome and cytokine-directed therapies

4. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial

5. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment pattern and changes in oral glucocorticoid dose after tocilizumab treatment in patients with adult Still's disease: An analysis of a Japanese claims database;International Journal of Rheumatic Diseases;2023-08-06

2. Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19;Frontiers in Immunology;2023-07-06

3. Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry;Seminars in Arthritis and Rheumatism;2022-12

4. Genetic and pharmacological targeting of GSDMD ameliorates systemic inflammation in macrophage activation syndrome;Journal of Autoimmunity;2022-12

5. Adult-Onset Still’s Disease—A Complex Disease, a Challenging Treatment;International Journal of Molecular Sciences;2022-10-24